Alorfi Nasser M, Algarni Alanood S
Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, Makkah, Saudi Arabia.
Clin Pharmacol. 2022 Aug 3;14:61-67. doi: 10.2147/CPAA.S374741. eCollection 2022.
Obesity and overweight pose a threat to health and are more common than undernutrition among adults. It is categorized by fat accumulation and a body mass index (BMI) of > 30. A significant increase in worldwide obesity has been ongoing over several decades. Over the past few years, several strategies have been followed for weight management and to counteract the increasing prevalence of the disease; however, room for improvement with pharmacological options still exists. This review aimed to digest selected past clinical and experimental studies and understand the role of semaglutide treatment for obesity.
Articles related to the clinical uses of semaglutide, mechanism of action, pharmacokinetics, pharmacodynamics, and side effects of the drug were identified. Only studies with human subjects who used Semaglutide for obesity management were included and assessed.
Semaglutide promotes weight loss via appetite and hunger suppression, decreases energy intake, controls eating, and depresses the relative fondness for fatty, energy-dense foods. Moreover, the relationship between obesity and Semaglutide has been widely investigated, and most studies reveal the efficacy of Semaglutide on weight loss. Overall, the pharmacokinetics of semaglutide shows a drop in glycosylated hemoglobin A1c (HbA1c) and total body weight. The usual adverse effects observed in patients treated with Semaglutide include gastrointestinal adverse events, like nausea, vomiting, diarrhea, constipation, and abdominal cramps.
The findings from the review suggest that semaglutide appears to be beneficial, most notably in its contribution to weight reduction.
肥胖和超重对健康构成威胁，在成年人中比营养不良更为常见。它通过脂肪堆积和体重指数（BMI）大于30来分类。几十年来，全球肥胖率一直在显著上升。在过去几年中，人们采取了几种体重管理策略来应对该疾病日益增加的患病率；然而，药物治疗方案仍有改进空间。本综述旨在梳理过去选定的临床和实验研究，了解司美格鲁肽治疗肥胖症的作用。
确定了与司美格鲁肽的临床用途、作用机制、药代动力学、药效学和药物副作用相关的文章。仅纳入并评估了使用司美格鲁肽进行肥胖管理的人体研究。
司美格鲁肽通过抑制食欲和饥饿来促进体重减轻，减少能量摄入，控制饮食，并降低对高脂肪、高能量食物的偏好。此外，肥胖与司美格鲁肽之间的关系已得到广泛研究，大多数研究揭示了司美格鲁肽在减肥方面的疗效。总体而言，司美格鲁肽的药代动力学表现为糖化血红蛋白A1c（HbA1c）和总体重下降。使用司美格鲁肽治疗的患者常见的不良反应包括胃肠道不良事件，如恶心呕吐、腹泻、便秘和腹部绞痛。
该综述的结果表明，司美格鲁肽似乎有益，最显著的是它对体重减轻的作用。
